Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer Postgenome Cohort – a cross-sectional analysis
<p>Abstract</p> <p>Background</p> <p>Hormone replacement therapy use (HRT) is associated with increased breast cancer risk. Our primary objective was to explore hormone levels in plasma according to HRT use, body mass index (BMI) and menopausal status. A secondary objec...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-01-01
|
| Series: | BMC Women's Health |
| Online Access: | http://www.biomedcentral.com/1472-6874/8/1 |
| _version_ | 1818213602661761024 |
|---|---|
| author | Olsen Karina S Dumeaux Vanessa Bakken Kjersti Waaseth Marit Rylander Charlotta Figenschau Yngve Lund Eiliv |
| author_facet | Olsen Karina S Dumeaux Vanessa Bakken Kjersti Waaseth Marit Rylander Charlotta Figenschau Yngve Lund Eiliv |
| author_sort | Olsen Karina S |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Hormone replacement therapy use (HRT) is associated with increased breast cancer risk. Our primary objective was to explore hormone levels in plasma according to HRT use, body mass index (BMI) and menopausal status. A secondary objective was to validate self-reported questionnaire information on menstruation and HRT use in the Norwegian Women and Cancer postgenome cohort (NOWAC).</p> <p>Methods</p> <p>We conducted a cross-sectional study of sex hormone levels among 445 women aged 48–62 who answered an eight-page questionnaire in 2004 and agreed to donate a blood sample. The samples were drawn at the women's local general physician's offices in the spring of 2005 and sent by mail to NOWAC, Tromsø, together with a two-page questionnaire. Plasma levels of sex hormones and Sex Hormone Binding Globulin (SHBG) were measured by immunometry. 20 samples were excluded, leaving 425 hormone measurements.</p> <p>Results</p> <p>20% of postmenopausal women were HRT users. The plasma levels of estradiol (E<sub>2</sub>) increased with an increased E<sub>2 </sub>dose, and use of systemic E<sub>2</sub>-containing HRT suppressed the level of Follicle Stimulating Hormone (FSH). SHBG levels increased mainly among users of oral E<sub>2 </sub>preparations. Vaginal E<sub>2 </sub>application did not influence hormone levels. There was no difference in BMI between HRT users and non-users. Increased BMI was associated with increased E<sub>2 </sub>and decreased FSH and SHBG levels among non-users. Menopausal status defined by the two-page questionnaire showed 92% sensitivity (95% CI 89–96%) and 73% specificity (95% CI 64–82%), while the eight-page questionnaire showed 88% sensitivity (95% CI 84–92%) and 87% specificity (95% CI 80–94%). Current HRT use showed 100% specificity and 88% of the HRT-users had plasma E<sub>2 </sub>levels above the 95% CI of non-users.</p> <p>Conclusion</p> <p>Users of systemic E<sub>2</sub>-containing HRT preparations have plasma E<sub>2 </sub>and FSH levels comparable to premenopausal women. BMI has an influence on hormone levels among non-users. NOWAC questionnaires provide valid information on current HRT use and menopausal status among Norwegian women who are between 48 and 62 years old.</p> |
| first_indexed | 2024-12-12T06:06:54Z |
| format | Article |
| id | doaj.art-7033f2b871f3434cb91368a01736c578 |
| institution | Directory Open Access Journal |
| issn | 1472-6874 |
| language | English |
| last_indexed | 2024-12-12T06:06:54Z |
| publishDate | 2008-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Women's Health |
| spelling | doaj.art-7033f2b871f3434cb91368a01736c5782022-12-22T00:35:16ZengBMCBMC Women's Health1472-68742008-01-0181110.1186/1472-6874-8-1Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer Postgenome Cohort – a cross-sectional analysisOlsen Karina SDumeaux VanessaBakken KjerstiWaaseth MaritRylander CharlottaFigenschau YngveLund Eiliv<p>Abstract</p> <p>Background</p> <p>Hormone replacement therapy use (HRT) is associated with increased breast cancer risk. Our primary objective was to explore hormone levels in plasma according to HRT use, body mass index (BMI) and menopausal status. A secondary objective was to validate self-reported questionnaire information on menstruation and HRT use in the Norwegian Women and Cancer postgenome cohort (NOWAC).</p> <p>Methods</p> <p>We conducted a cross-sectional study of sex hormone levels among 445 women aged 48–62 who answered an eight-page questionnaire in 2004 and agreed to donate a blood sample. The samples were drawn at the women's local general physician's offices in the spring of 2005 and sent by mail to NOWAC, Tromsø, together with a two-page questionnaire. Plasma levels of sex hormones and Sex Hormone Binding Globulin (SHBG) were measured by immunometry. 20 samples were excluded, leaving 425 hormone measurements.</p> <p>Results</p> <p>20% of postmenopausal women were HRT users. The plasma levels of estradiol (E<sub>2</sub>) increased with an increased E<sub>2 </sub>dose, and use of systemic E<sub>2</sub>-containing HRT suppressed the level of Follicle Stimulating Hormone (FSH). SHBG levels increased mainly among users of oral E<sub>2 </sub>preparations. Vaginal E<sub>2 </sub>application did not influence hormone levels. There was no difference in BMI between HRT users and non-users. Increased BMI was associated with increased E<sub>2 </sub>and decreased FSH and SHBG levels among non-users. Menopausal status defined by the two-page questionnaire showed 92% sensitivity (95% CI 89–96%) and 73% specificity (95% CI 64–82%), while the eight-page questionnaire showed 88% sensitivity (95% CI 84–92%) and 87% specificity (95% CI 80–94%). Current HRT use showed 100% specificity and 88% of the HRT-users had plasma E<sub>2 </sub>levels above the 95% CI of non-users.</p> <p>Conclusion</p> <p>Users of systemic E<sub>2</sub>-containing HRT preparations have plasma E<sub>2 </sub>and FSH levels comparable to premenopausal women. BMI has an influence on hormone levels among non-users. NOWAC questionnaires provide valid information on current HRT use and menopausal status among Norwegian women who are between 48 and 62 years old.</p>http://www.biomedcentral.com/1472-6874/8/1 |
| spellingShingle | Olsen Karina S Dumeaux Vanessa Bakken Kjersti Waaseth Marit Rylander Charlotta Figenschau Yngve Lund Eiliv Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer Postgenome Cohort – a cross-sectional analysis BMC Women's Health |
| title | Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer Postgenome Cohort – a cross-sectional analysis |
| title_full | Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer Postgenome Cohort – a cross-sectional analysis |
| title_fullStr | Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer Postgenome Cohort – a cross-sectional analysis |
| title_full_unstemmed | Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer Postgenome Cohort – a cross-sectional analysis |
| title_short | Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer Postgenome Cohort – a cross-sectional analysis |
| title_sort | hormone replacement therapy use and plasma levels of sex hormones in the norwegian women and cancer postgenome cohort a cross sectional analysis |
| url | http://www.biomedcentral.com/1472-6874/8/1 |
| work_keys_str_mv | AT olsenkarinas hormonereplacementtherapyuseandplasmalevelsofsexhormonesinthenorwegianwomenandcancerpostgenomecohortacrosssectionalanalysis AT dumeauxvanessa hormonereplacementtherapyuseandplasmalevelsofsexhormonesinthenorwegianwomenandcancerpostgenomecohortacrosssectionalanalysis AT bakkenkjersti hormonereplacementtherapyuseandplasmalevelsofsexhormonesinthenorwegianwomenandcancerpostgenomecohortacrosssectionalanalysis AT waasethmarit hormonereplacementtherapyuseandplasmalevelsofsexhormonesinthenorwegianwomenandcancerpostgenomecohortacrosssectionalanalysis AT rylandercharlotta hormonereplacementtherapyuseandplasmalevelsofsexhormonesinthenorwegianwomenandcancerpostgenomecohortacrosssectionalanalysis AT figenschauyngve hormonereplacementtherapyuseandplasmalevelsofsexhormonesinthenorwegianwomenandcancerpostgenomecohortacrosssectionalanalysis AT lundeiliv hormonereplacementtherapyuseandplasmalevelsofsexhormonesinthenorwegianwomenandcancerpostgenomecohortacrosssectionalanalysis |